Residents' Association Werdenberg


17 PATIENT COUNSELING INFORMATION

Dapoxetin > sildenafil dapoxetine tablets


To decrease the chance of adverse reactions in patients taking ritonavir, a decrease in sildenafil dosage is recommended [ see Dosage and Administration (2.4), Drug Interactions (7.4), and Clinical Pharmacology (12.3)].

Region Typical Price Range (USD) Availability Notes
North America 20-50 per pack Widely available through pharmacies Prescription often required
Europe 15-45 per pack Over-the-counter and prescription options Varies by country
Asia 10-30 per pack Readily accessible in many markets Often lower cost
Online Pharmacies Price varies Ensure reputable sources Beware of counterfeit products

The safety and efficacy of combinations of sildenafil tablets with other PDE5 Inhibitors, including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied.

  • Sildenafil is not recommended for use by women.
  • Dapoxetine is approved specifically for men with PE.
  • Both drugs help improve sexual confidence and performance.
  • Proper hydration can help mitigate side effects.
  • Patients with retinal disorders should consult a healthcare professional.
  • Use of these medications does not protect against sexually transmitted infections.
  • Combining medications without medical guidance can be dangerous.
  • Inform your doctor if you experience any adverse reactions.

Therefore, the use of such combinations is not recommended. There have been postmarketing reports of bleeding events in patients who have taken sildenafil tablets.

2.4 Dosage Adjustments Due to Drug Interactions

Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [ see Drug Interactions (7.2)and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting). Consideration should be given to the following: Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [ see Dosage and Administration (2.3)].

Patients and Methods

In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. Sildenafil tablets has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-hypertensive medications. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and sildenafil tablets, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [ see Clinical Pharmacology (12.2)]. In addition, the combination of heparin and sildenafil tablets had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans.

Parameter Value Notes
Absorption Rate Rapid Peak plasma in 1-2 hours
Half-Life 21 hours Longer duration for sustained effect
Metabolism Liver (CYP2D6 and CYP3A4) Biotransformation process
Excretion Urine Main route of elimination

The safety of sildenafil tablets is unknown in patients with bleeding disorders and patients with active peptic ulceration.

Product Dosage Quantity + Bonus Price
Kamagra Effervescent Tablets100 mg14 Pills51.61€ 49.15€
Priligy Generic Dapoxetine60mg60 + 8 Pills183.06€ 174.34€
Kamagra Effervescent Tablets100 mg42 + 7 Pills122.97€ 117.11€
Levitra Original20mg34 + 2 Pills188.51€ 179.53€
Priligy Generic Dapoxetine60mg10 Pills47.63€ 45.36€
Priligy Generic Dapoxetine60mg90 + 10 Pills265.64€ 252.99€
Viagra Generic100mg60 + 4 Pills96.36€ 91.77€
Priligy Generic Dapoxetine60mg20 + 4 Pills77.31€ 73.63€
Cialis Original20mg12 Pills78.32€ 74.59€
Cialis Professional20mg30 Pills104.57€ 99.59€
Priligy Generic Dapoxetine60mg180 + 10 Pills494.76€ 471.20€
Priligy Generic Dapoxetine60mg30 + 6 Pills106.65€ 101.57€
Kamagra Polo100mg84 + 4 Pills244.49€ 232.85€
Priligy Generic Dapoxetine60mg120 + 10 Pills341.26€ 325.01€
Cialis Professional20mg20 Pills78.33€ 74.60€

The use of sildenafil tablets offers no protection against sexually transmitted diseases.

  • Consistent use of sildenafil can help maintain erectile function.
  • Dapoxetine provides a pharmacological solution for PE.
  • Both products should be stored in a cool, dry place away from children.
  • Side effects may diminish with continued use or dose adjustment.
  • Some patients may require alternative therapies if side effects occur.
  • Clinical guidelines recommend consultation before combining treatments.
  • Dapoxetine's short half-life minimizes residual effects.
  • Patients should inform healthcare providers about all current medications.

6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling:Cardiovascular [see Warnings and Precautions (5.1)]Prolonged Erection and Priapism [see Warnings and Precautions (5.2)]Effects on the Eye [see Warnings and Precautions (5.3)]Hearing Loss [see Warnings and Precautions (5.4)]Hypotension when Co-administered

7.5 Alcohol

In addition, the combination of heparin and sildenafil tablets had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans.The safety of sildenafil tablets is unknown in patients with bleeding disorders and patients with active peptic ulceration.5.9 Counseling Patients about Sexually Transmitted DiseasesThe use of sildenafil tablets offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered. There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment. Sildenafil tablets has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [ see Clinical Pharmacology (12.2)].

Product Sodium Picosulfate Oral Solution BP 5 mg/5ml

While this normally would be expected to be of little consequence in most patients, prior to prescribing sildenafil tablets, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil tablets – those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure. There are no controlled clinical data on the safety or efficacy of sildenafil tablets in the following groups; if prescribed, this should be done with caution. Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); Patients with cardiac failure or coronary artery disease causing unstable angina. Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil tablets. with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions (5.5)]Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions (5.6)]Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions (5.7)]Effects on Bleeding [see Warnings and Precautions (5.8)]Counseling Patients About Sexually

Is Priligy available through the NHS?

If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Sildenafil tablets should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle sildenafil and dapoxetine cell anemia, multiple myeloma, or leukemia). However, there are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with sickle cell or related anemias. Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil tablets, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [ see Adverse Reactions (6.2)].

Product Tadalafil tablets USP 10 mg

Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals with "crowded" optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including sildenafil tablets, for this uncommon condition. There are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil tablets, and seek prompt medical attention in the event of sudden decrease or loss of hearing. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [ see Adverse Reactions (6.1, 6.2) ]. Transmitted Diseases [see Warnings and Precautions(5.9)]The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates

  • Sildenafil can cause a drop in blood pressure in some users.
  • Dapoxetine's adverse effects are usually mild and transient.
  • Patients on medication for heart disease should consult a doctor first.
  • Sexual activity itself can pose risks for some health conditions.
  • Combining sildenafil with other ED medications is not recommended.
  • Dapoxetine may interact with other serotonergic drugs.
  • Use caution when operating machinery after taking these drugs.
  • Always inform your doctor about other medications being used.

observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Sildenafil tablets was administered to over 3700 patients (aged 19–87 years) during pre-marketing clinical trials worldwide.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor.Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs.Sildenafil tablets has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-hypertensive medications.In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and sildenafil tablets, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [ see Clinical Pharmacology (12.2)].5.6 Adverse Reactions with the Concomitant Use of RitonavirThe concomitant administration of the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil (11-fold increase in AUC). If sildenafil tablets are prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of sildenafil are limited. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200–800 mg). To decrease the chance of adverse reactions in patients taking ritonavir, a decrease in sildenafil dosage is recommended [ see Dosage and Administration (2.4), Drug Interactions (7.4), and Clinical Pharmacology (12.3)].5.7 Combination with other PDE5 Inhibitors or Other Erectile Dysfunction TherapiesThe safety and efficacy of combinations of sildenafil tablets with other PDE5 Inhibitors, including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied.

Serious side effects

Such combinations may further lower blood pressure. Therefore, the use of such combinations is not recommended.5.8 Effects on BleedingThere have been postmarketing reports of bleeding events in patients who have taken sildenafil tablets. A causal relationship between sildenafil tablets and these events has not been established. In humans, sildenafil tablets have no effect on bleeding time when taken alone or with aspirin. However, in vitrostudies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor).